⚠ Evidence warning: Clinical trials or other evidence do not support the claims that ginkgo improves or stabilises normal-tension glaucoma, dry macular degeneration or early diabetic eye disease. This page keeps it as a report of what people, websites or other media say.

Ginkgo Biloba for Vision and Macular Degeneration

Vision and Macular Degeneration — scientific infographic poster

The eye, like the inner ear, is a microcirculation-dependent organ: the retina is the most metabolically active tissue in the body per unit weight, and the choroidal and retinal vessels supplying it are end-arteries with limited collateral reserve. This is the conceptual reason why ginkgo's mechanism — platelet-activating factor (PAF) antagonism, flavonoid antioxidant protection, and erythrocyte deformability improvement — has been hypothesized and tested in three distinct ophthalmologic conditions: normal-tension glaucoma (where the optic nerve is damaged despite normal intraocular pressure (IOP), implicating vascular insufficiency), age-related macular degeneration (where chronic choroidal microcirculatory dysfunction contributes to photoreceptor loss), and diabetic retinopathy (the classic microvascular endpoint of diabetes). The Fies & Dienel 2002 trial in dry age-related macular degeneration (AMD) reported visual acuity improvement with the extract EGb 761 at two doses, without a placebo group; the Quaranta 2003 crossover trial in normal-tension glaucoma reported visual field improvement, and a 2014 trial of the same dose and design did not repeat it; the cochlear-retinal microcirculation parallel ties the ophthalmologic evidence to the broader ginkgo mechanism. The evidence base is smaller and less consistent than for cognitive or peripheral artery disease (PAD) indications. Practitioners describe ginkgo as an add-on for eye disease of microcirculatory origin on the strength of its proposed mechanism.


Table of Contents

  1. The Eye as a Microcirculation-Dependent Organ
  2. The Cochlear-Retinal Parallel
  3. Fies & Dienel 2002 — The Age-Related Macular Degeneration Trial
  4. Quaranta 2003 — Normal-Tension Glaucoma
  5. Age-Related Macular Degeneration — Mechanism & Trials
  6. Glaucoma — NTG vs POAG
  7. Diabetic Retinopathy
  8. Direct Retinal Blood Flow Measurement
  9. The AREDS Question — Why Ginkgo Is Not in the Formula
  10. Doses Used in Trials and in Practice
  11. Cautions — Retrobulbar Hemorrhage and Glaucoma Drug Interactions
  12. Key Research Papers
  13. Connections
  14. Featured Videos

The Eye as a Microcirculation-Dependent Organ

The retina's metabolic demand is exceptional. The outer retina (photoreceptors and retinal pigment epithelium, RPE) consumes oxygen at one of the highest rates of any tissue in the body — the photoreceptors maintain a continuous dark current that requires constant adenosine triphosphate (ATP) supply, and the renewal of photoreceptor outer segments is one of the most metabolically demanding processes in adult cell biology. The retinal pigment epithelium phagocytizes shed outer segment discs daily, generating lipofuscin and reactive oxygen species at high rates.

This metabolic demand is supplied by two distinct vascular systems:

  1. The retinal vasculature — the central retinal artery and its branches supply the inner retina (ganglion cell layer, inner nuclear layer, inner plexiform layer). These vessels are visible on fundoscopy. Their dysfunction produces diabetic retinopathy, retinal vein occlusion, and the inner-retinal layer ischemia of arterial occlusive disease.
  2. The choroidal vasculature — a dense network of fenestrated capillaries (the choriocapillaris) supplies the outer retina (photoreceptors and retinal pigment epithelium) by diffusion across Bruch's membrane. The choroid has the highest blood flow per gram of tissue of any organ in the body. Choroidal microcirculatory dysfunction is implicated in age-related macular degeneration.

The optic nerve has its own distinct microcirculation, supplied by branches of the short posterior ciliary arteries. The optic nerve head circulation is exquisitely sensitive to perfusion pressure (the difference between blood pressure and intraocular pressure), and chronic optic nerve ischemia is the proposed mechanism behind normal-tension glaucoma.

All three vascular beds — retinal, choroidal, and optic nerve head — share the basic structural and functional properties that make them susceptible to ginkgo's microcirculatory mechanism: end-artery anatomy, high metabolic demand, sensitivity to viscosity and erythrocyte deformability, vulnerability to PAF-mediated platelet aggregation and leukocyte adhesion in capillaries, and dependence on adequate endothelial nitric oxide signaling for flow regulation. The clinical question is whether the mechanistic plausibility translates to measurable clinical benefit in patients with established ophthalmologic disease.

Back to Table of Contents

The Cochlear-Retinal Parallel

The most elegant conceptual frame for understanding ginkgo's ophthalmologic potential is the cochlear-retinal microcirculation parallel. The cochlea and the retina share an unusual set of structural features that no other major organs share:

The clinical correlate of this anatomical parallel is the well-documented epidemiologic association between hearing loss and visual impairment in aging populations (dual sensory impairment increases dramatically after age 70), and the parallel mechanistic case for ginkgo in both cochlear ischemia (tinnitus, sudden sensorineural hearing loss) and retinal ischemia (normal-tension glaucoma, age-related macular degeneration). For the cochlear side of this parallel, see our Tinnitus page.

Back to Table of Contents

Fies & Dienel 2002 — The Age-Related Macular Degeneration Trial

The reference trial for ginkgo in age-related macular degeneration is Fies P & Dienel A (2002) "Ginkgo extract in impaired vision — treatment with special extract EGb 761 of impaired vision due to dry senile macular degeneration," published in Wiener Medizinische Wochenschrift. This was a randomized double-blind dose-comparison trial of two EGb 761 doses (60 mg/day vs 240 mg/day) in 99 patients with dry (non-neovascular) age-related macular degeneration over 6 months.

The primary outcome was change in corrected visual acuity in the more severely affected eye. Secondary outcomes included near visual acuity, contrast sensitivity, and patient-reported visual function.

Results:

The Fies & Dienel trial has several methodologic limitations: there was no placebo arm (both dose groups received active drug, which limits inference about absolute effect size); the trial was relatively short (6 months) for an age-related macular degeneration outcome; the sample size was modest; the visual acuity improvement was small enough that its clinical significance is debatable in the context of a slowly progressive degenerative disease.

The trial used the same 240 mg/day dose as the cognitive and peripheral artery disease trials, and it did not show a statistically significant difference between doses. The authors concluded that the extract was effective in dry age-related macular degeneration. It has not been followed by large definitive placebo-controlled trials, partly because the modern age-related macular degeneration treatment landscape has been dominated by supplementation from the Age-Related Eye Disease Study (AREDS) and (for wet age-related macular degeneration) anti-vascular endothelial growth factor (anti-VEGF) intravitreal injections.

Back to Table of Contents

Quaranta 2003 — Normal-Tension Glaucoma

The reference trial for ginkgo in glaucoma is Quaranta L, Bettelli S, Uva MG, Semeraro F, Turano R, Gandolfo E (2003) "Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma," published in Ophthalmology. This was a randomized double-blind crossover trial in 27 patients with bilateral normal-tension glaucoma (NTG), comparing ginkgo extract 40 mg three times daily vs placebo for 4 weeks each, with an 8-week washout between phases.

Normal-tension glaucoma is the variant of primary open-angle glaucoma in which intraocular pressure is consistently within the statistically normal range (under 22 mmHg) but progressive optic nerve damage and visual field loss occur. The proposed mechanism is vascular dysregulation at the optic nerve head — impaired autoregulation of optic nerve perfusion, vasospasm of the short posterior ciliary arteries, and impaired endothelial function. NTG is the glaucoma subtype with the strongest mechanistic case for ginkgo benefit.

The primary outcome was change in Humphrey visual field mean defect (a quantitative measure of visual field loss in decibels; the larger the loss, the more damage).

Results:

This was a striking result — visual field improvement in a chronic neurodegenerative condition is uncommon. The trial's limitations are the small sample size (n=27), the short treatment duration (4 weeks per arm), and the crossover design (which can be vulnerable to carryover effects in glaucoma trials). The result has been broadly cited as supporting the NTG-specific ginkgo indication. The closest repeat did not reproduce it: a 2014 Chinese crossover trial used the same dose and design in 35 people with normal-tension glaucoma, 28 of whom completed testing. Changes in visual field and contrast sensitivity did not differ between ginkgo and placebo (P > 0.2), and the authors concluded that the extract “had no effect on mean defect or contrast sensitivity.”

In practice: some practitioners add ginkgo extract for normal-tension glaucoma patients who are already on maximum tolerable IOP-lowering therapy (prostaglandin analogs, beta-blockers, alpha agonists, carbonic anhydrase inhibitors, rho kinase inhibitors) and who continue to show visual field progression. The 240 mg/day often used in practice is double the 120 mg/day this trial gave, and the evidence base is small.

Back to Table of Contents

Age-Related Macular Degeneration — Mechanism & Trials

Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in adults over 65 in developed countries. It exists in two major forms:

The mechanistic case for ginkgo in dry age-related macular degeneration has several components:

  1. Choroidal microcirculation — choroidal blood flow declines progressively with age, and impaired choroidal perfusion has been documented in dry age-related macular degeneration using indocyanine green (ICG) angiography and optical coherence tomography (OCT) angiography. Ginkgo's PAF-antagonist and flavonoid-NO mechanisms target the same microcirculation
  2. Oxidative stress reduction — oxidative damage to the RPE is a major driver of dry age-related macular degeneration progression. Flavonoid antioxidant scavenging of reactive oxygen species in the RPE is mechanistically protective
  3. Reduced inflammatory cell adhesion — chronic low-grade choroidal inflammation contributes to age-related macular degeneration progression. Ginkgolide-B's PAF antagonism reduces PAF-mediated leukocyte adhesion and chemotaxis
  4. Iron and copper chelation — iron accumulation in the RPE contributes to oxidative stress through Fenton-reaction free-radical generation. Flavonoid metal chelation may modestly reduce this oxidative burden

The Cochrane 2013 review of ginkgo for age-related macular degeneration (Evans 2013) included only 2 trials with 119 patients and concluded that the question of whether people with age-related macular degeneration should take ginkgo to slow the disease “has not been answered by research to date,” adding that two small trials “have suggested possible benefit of Gingko biloba on vision and further trials are warranted.” The Fies & Dienel 2002 trial and the Lebuisson 1986 trial (the original French trial that showed visual acuity improvement with EGb 761 vs placebo) are the most-cited individual trials, but neither was large or definitive.

Where it sits: ginkgo has not been tested as a replacement for AREDS / AREDS2 supplementation (which has high-quality evidence in the appropriate age-related macular degeneration population) or for anti-VEGF injection in wet age-related macular degeneration. Some people with dry age-related macular degeneration take it alongside other supplements; the evidence is modest. For more on age-related macular degeneration see our Macular Degeneration page.

Back to Table of Contents

Glaucoma — NTG vs POAG

The positive ginkgo glaucoma reports come mostly from normal-tension glaucoma rather than primary open-angle glaucoma (POAG), though results in normal-tension glaucoma are mixed too. The proposed reason is the underlying mechanism — NTG is the glaucoma subtype with the strongest vascular component, while elevated-pressure POAG is dominated by mechanical injury to retinal ganglion cell axons at the optic nerve head.

The Ritch 2000 hypothesis paper "Potential role for Ginkgo biloba extract in the treatment of glaucoma" in Medical Hypotheses is the most-cited theoretical framework for ginkgo in NTG and remains the conceptual basis for clinical use in this specific subtype. The 2012 Cybulska-Heinrich paper is a narrative review offering what it calls a scientific opinion on ginkgo as an adjuvant in glaucoma, not a patient series. For more on glaucoma management, see our Glaucoma page.

Back to Table of Contents

Diabetic Retinopathy

Diabetic retinopathy is the leading cause of vision loss in working-age adults in developed countries. It is fundamentally a microvascular disease of the retina, with two major stages:

The mechanistic case for ginkgo in early NPDR is the same as in other microvascular indications: PAF antagonism reduces microvascular thrombosis and leukocyte adhesion, flavonoid antioxidant scavenging reduces hyperglycemia-induced oxidative damage, and improved erythrocyte deformability improves flow through narrowed capillaries.

The Lanthony & Cosson 1988 double-blind trial in 29 people with early diabetic retinopathy measured color vision (an early functional marker of retinal dysfunction in diabetes) over 6 months and reported a tendency to improvement with ginkgo extract and worsening on placebo. The improvement reached statistical significance only on one color test (the Desaturated Panel D-15) among people without retinal ischemia. Subsequent small trials have suggested benefit on visual field, retinal sensitivity, and microaneurysm count. The evidence base is too small to be definitive.

In practice: for people with established diabetes and early NPDR (no center-involving edema, no proliferative changes), practitioners describe ginkgo at 240 mg/day as an add-on to glycemic control, statin therapy, blood pressure control, and angiotensin-converting enzyme inhibitor (ACE inhibitor) therapy. It has not been tested as a replacement for those treatments. In proliferative disease, ginkgo has no documented role and the bleeding-risk concern is amplified by the underlying retinal vascular fragility.

Back to Table of Contents

Direct Retinal Blood Flow Measurement

Blood flow in the eye has been measured directly before and after ginkgo. Studies using color Doppler imaging, a laser flowmeter, laser Doppler velocimetry, and OCT angiography point in both directions:

The OCT angiography era (post-2014) has enabled quantitative measurement of macular and peripapillary capillary perfusion at much higher resolution than was previously possible. OCT angiography studies of ginkgo's effects on retinal capillary perfusion are still few; the 2025 Hodgson trial above did not find the improvement the mechanism predicts, and its authors said larger studies are needed.

Back to Table of Contents

The AREDS Question — Why Ginkgo Is Not in the Formula

A frequent patient question is why ginkgo is not included in the AREDS or AREDS2 supplementation formula, given its plausibility for age-related macular degeneration. The answer reflects the trial-design history rather than a definitive judgment about ginkgo's efficacy:

In short: AREDS or AREDS2 is the nutritional intervention with the stronger evidence for intermediate-stage dry age-related macular degeneration. Ginkgo extract has smaller and less consistent evidence.

Back to Table of Contents

Doses Used in Trials and in Practice

Back to Table of Contents

Cautions — Retrobulbar Hemorrhage and Glaucoma Drug Interactions

Back to Table of Contents

Key Research Papers

  1. Quaranta L, Bettelli S, Uva MG, Semeraro F, Turano R, Gandolfo E (2003). Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma. Ophthalmology 110(2):359-362. — PubMed PMID: 12578781
  2. Fies P, Dienel A (2002). Ginkgo extract in impaired vision — treatment with special extract EGb 761 of impaired vision due to dry senile macular degeneration. Wiener Medizinische Wochenschrift 152(15-16):423-426. — PubMed PMID: 12244891
  3. Evans JR (2013). Ginkgo biloba extract for age-related macular degeneration. Cochrane Database of Systematic Reviews (1):CD001775. — PubMed PMID: 23440785
  4. Lebuisson DA, Leroy L, Rigal G (1986). Treatment of senile macular degeneration with Ginkgo biloba extract. A preliminary double-blind drug versus placebo study. Presse Med 15(31):1556-1558. — PubMed PMID: 2947098
  5. Park JW, Kwon HJ, Chung WS, Kim CY, Seong GJ (2011). Short-term effects of Ginkgo biloba extract on peripapillary retinal blood flow in normal tension glaucoma. Korean Journal of Ophthalmology 25(5):323-328. — PubMed PMID: 21976939
  6. Cybulska-Heinrich AK, Mozaffarieh M, Flammer J (2012). Ginkgo biloba: an adjuvant therapy for progressive normal and high tension glaucoma. Molecular Vision 18:390-402. — PubMed PMID: 22355250
  7. Ritch R (2000). Potential role for Ginkgo biloba extract in the treatment of glaucoma. Medical Hypotheses 54(2):221-235. — PubMed PMID: 10790757
  8. Chung HS, Harris A, Kristinsson JK, Ciulla TA, Kagemann C, Ritch R (1999). Ginkgo biloba extract increases ocular blood flow velocity. Journal of Ocular Pharmacology and Therapeutics 15(3):233-240. — PubMed PMID: 10385132
  9. Hirooka K, Tokuda M, Miyamoto O, Itano T, Baba T, Shiraga F (2004). The Ginkgo biloba extract (EGb 761) provides a neuroprotective effect on retinal ganglion cells in a rat model of chronic glaucoma. Current Eye Research 28(3):153-157. — PubMed PMID: 14977516
  10. Lanthony P, Cosson JP (1988). The course of color vision in early diabetic retinopathy treated with Ginkgo biloba extract. Journal Français d'Ophtalmologie 11(10):671-674. — PubMed PMID: 3072365
  11. Wimpissinger B, Berisha F, Garhoefer G, Polak K, Schmetterer L (2007). Influence of Ginkgo biloba on ocular blood flow. Acta Ophthalmologica Scandinavica 85(4):445-449. — PubMed PMID: 17324220
  12. Mozaffarieh M, Flammer J (2007). Is there more to glaucoma treatment than lowering IOP? Survey of Ophthalmology 52 Suppl 2:S174-179. — PubMed PMID: 17998043
  13. Guo X, Kong X, Huang R, Jin L, Ding X, He M, Liu X, Patel MC, Congdon NG (2014). Effect of Ginkgo biloba on visual field and contrast sensitivity in Chinese patients with normal tension glaucoma: a randomized, crossover clinical trial. Investigative Ophthalmology & Visual Science 55(1):110-6. — PubMed PMID: 24282229
  14. Prinz J, Prokosch V, Wang X, Feng Y, Walter P, Fuest M, Migliorini F (2025). Efficacy of Ginkgo biloba on parameters in glaucoma: A systematic review. PLoS One 20(2):e0314644. — PubMed PMID: 39951447
  15. Lee J, Sohn SW, Kee C (2013). Effect of Ginkgo biloba extract on visual field progression in normal tension glaucoma. Journal of Glaucoma 22(9):780-4. — PubMed PMID: 22595937
  16. Hodgson K, Palakkamanil MM, Zhang A, Dyachok OM, Smith CA, Nicolela MT, Chauhan BC, Shuba LM (2025). Effect of ginkgo biloba extract on macula and peripapillary perfusion examined using optical coherence tomography angiography. Canadian Journal of Ophthalmology 60(4):e566-e571. — PubMed PMID: 39961352
  17. Fong KC, Kinnear PE (2003). Retrobulbar haemorrhage associated with chronic Gingko biloba ingestion. Postgraduate Medical Journal 79(935):531-2. — PubMed PMID: 13679551
  18. Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, et al. (2023). Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet 402(10411):1434-1448. — PubMed PMID: 37865470
  19. Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA, et al. (2023). Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet 402(10411):1449-1458. — PubMed PMID: 37696275

PubMed Topic Searches

  1. PubMed: Ginkgo for macular degeneration
  2. PubMed: Ginkgo for glaucoma (NTG)
  3. PubMed: Ginkgo retinal/ocular blood flow
  4. PubMed: Ginkgo for diabetic retinopathy
  5. PubMed: RGC neuroprotection

Back to Table of Contents

Connections

Back to Table of Contents